6,8-Dichlorochroman-4-amine | 886762-89-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6,8-Dichlorochroman-4-amine
• 英文别名: 6,8-dichloro-3,4-dihydro-2H-chromen-4-amine
• CAS: 886762-89-6
• 化学式: C₉H₉Cl₂NO
• 分子量: 218.08
• InChiKey: KJGMEAMNMDDGQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM<br/>[FR] COMPOSÉS DOTÉS D'UNE ACTIVITÉ ANTIBACTÉRIENNE DIRIGÉE CONTRE CLOSTRIDIUM
  申请人：ELANCO ANIMAL HEALTH IRELAND

  公开号：WO2012017030A1

  公开（公告）日：2012-02-09

  The present invention is related to novel compounds of formula (I) having antibacterial activity against Clostridium bacteria, in particular Clostridium perfringens, pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及具有抗菌活性的新型化合物（I）的公式，特别针对梭状芽孢杆菌，尤其是产气荚膜梭状芽孢杆菌，包括这些化合物的药物组合物，以及制备这些化合物的化学过程。
• COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM
  申请人：Guillemont Jerome Emile Georges

  公开号：US20130109694A1

  公开（公告）日：2013-05-02

  The present invention is related to novel compounds of formula (I) having antibacterial activity against Clostridium bacteria, in particular Clostridium perfringens , pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

  本发明涉及具有抗Clostridium菌活性的新型化合物(I)的药物，特别是针对Clostridium perfringens，以及包含这些化合物的药物组合物和制备这些化合物的化学过程。
• Anthelmintic quinoline-3-carboxamide derivatives
  申请人：Bayer Animal Health GMBH

  公开号：US10889573B2

  公开（公告）日：2021-01-12

  The present invention covers new quinoline compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）的新喹啉化合物（其中 A、R1、R2、R3、R4、R5、R6 和 Q 如本文所定义）、制备所述化合物的方法、用于制备所述化合物的中间体化合物、包含所述化合物的药物组合物和组合物，以及使用所述化合物制造用于治疗、控制和/或预防疾病（尤其是蠕虫感染）的药物组合物，作为单独制剂或与其他活性成分组合使用。
• Specific inhibitors of methionyl-tRNA synthetase
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US10913736B2

  公开（公告）日：2021-02-09

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.

  本公开总体上涉及可用于抑制 MetRS 的组合物，以及通过抑制 MetRS 改善疾病的治疗方法。
• SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20170275279A1

  公开（公告）日：2017-09-28

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.